ImetelChat

Earfool, nice to see you here. Scotty, I suspect the reason Dr. T considered the MDS response meager was that he was comparing it to the response in MF (so a strong endorsement of Rx in MF). Reading between the lines there was probably no bone marrow reversal (they certainly didn't mention bone marr...

Fisher and Scotty, if meager gets you transfusion independence, that's pretty important and still valuable. Nonetheless, Fishers point about combo therapy suggests Janssen has just begun to fight. bp

Scotty, from recent Blood Journal, kindly referenced by Fisher <<The current study suggests drug activity in imetelstat-treated patients with RARS or RARS-T. The meager depth of response in the current study, compared with the aforementioned report in myelofibrosis,1 might reflect either different d...

Scotty, I fear you have an oversimplified view of a very complex biocellular world. First <<should I be worried MDS response has been meager? >> Answer: (my view), yes. But it might be the best thing yet for MDS, not the magic bullet you want. As for platform, we have seen little re combo therapy in...

Thanks Fish, good thing I live in the great plains. (No cliffs to jump off of.)

Ditto that.

Sargasso, what is it that you want exactly? The company has released data via the NEJM supporting very important and new responses in major hematologic malignancies. The basic science data e.g. the heretofore discussed AACR abstracts confirm Dr. Lane's amazing mouse studies and show to further AMAZI...

AACR abstracts are up. I can't copy them for some reason or I would. Impressive synergy in AML therapy reducing viable AML cell line in one instance to 1 percent after only four weeks (what happened after that???) Check it out and let us know what you think. Regards, bp

Agreed, we'd need to see normalization of the bone marrow. No bone marrow data presented for MDS. bp

Agreed. Its pretty clear he is not on the J and J payroll from his disclaimers. This helps to keep his pristine reputation as an unbiased researcher. bp

<<Transfusion independence in MDS is a bit like reversal of fibrosis in MF.>> Perhaps. But the study notably omitted any bone marrow findings in MDS and there seems to be no correlate to CR and PR status. So the implication is palliation and avoidance of hemochromatosis rather than reversal of disea...

http://www.stvincent.org/uploadedFiles/ ... efferi.pdf



Enjoy. bp

I couldn't help but note that the recent Nature letter seemed a rehash of the already presented data in NEJM and was looking for a reason for the redundancy. Also Dr. T et al alluded to the relative "meager" response of MDS to Imet compared to MF. "Damned with faint praise!!" Here we have the potent...

Hi Irish, Phil and Fisher, Irish, the sun always rises a little earlier when I know you have posted. Fisher--looks like my modified list did fail to post, it was nothing great, I just tried to temper some of the unknown speculation (eg value of IP portfolio, and J and J statements re potential futur...

Fisher, did my last post (suggested modifications to your list) fail to post? Or did you feel it was too harsh to post. Please let me know bp

Fisher, old friend, I would say the wording is too inexact for my taste. For example to say the IMbark study has started at 80 sites is not correct in the total number of anticipated sites and the total number of sites actually enrolling currently. Rather than go line by line, you see my point. I li...

Fisher, you must not have "the Lone Ranger" in Europe. With a hat tip to Jay Silverheels, it means "one who looks out in solitude" or "trusted scout" with a few other variations also. Regards, bp

Not so fast Kemosabe: SEATTLE, Feb. 9, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today provided an update regarding the clinical studies being conducted under the Company's Investigational New Drug ("IND") application for pacritinib. Following the issuance of th...

Fisher to clarify, pacritinib is on FULL clinical hold not partial. This means as you know all patients must discontinue the drug. Big difference from the partial hold to which fda subjected Gern.

Yes, full clinical hold. Also please see my response to your prior note. bp